๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neo-Sequence 2๏ผšNCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
NCT06371586Gastric Cancer, Diffuse Type Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
67
Beijing
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Recruiting
Effect of Degenerative Spondylolisthesis on the Clinical Outcome of Unilateral Biportal Endoscopy for Lumbar Spinal Stenosis: Study Protocol
NCT06394089Degenerative Spondylolisthesis, Lumbar Spinal Stenosis
Beijing Friendship Hospital
Observational
150
Beijing
2024-03-01
Recruiting
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
NCT06321081RAS Mutation, Metastatic Colorectal Cancer, MSS
Beijing Hospital
Phase 2
60
Beijing
2024-03-01
Recruiting
Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction
NCT06489080Acute Myocardial Infarction, Coronary Artery Disease
Peking University First Hospital
Observational
10,000
Beijing
2024-03-01
Recruiting
The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease
NCT06501222Chronic Kidney Diseases
Yuanjun Yang
Not applicable
114
Beijing
2024-03-01
Recruiting
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
NCT06317558NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2024-03-01
Recruiting
A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine
NCT06203873PFO - Patent Foramen Ovale, Migraine, Migraine Headache, Migraine Headache, With or Without Aura
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
400
Beijing
2024-03-01
Recruiting
The Therapeutic Effect of Betaine in Syringomyelia
NCT06308367Syringomyelia
Xuanwu Hospital, Beijing
Phase 2
30
Beijing
2024-03
Recruiting
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
NCT06131450Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
138
Beijing
2024-02-29
Recruiting
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
NCT06231381Generalized Pustular Psoriasis (GPP)
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2
33
Beijing, Shanghai
2024-02-29
Active, closed
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
NCT06957379HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
78
Beijing
2024-02-29
Recruiting
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT06775405Respiratory Synctial Virus Infections
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Sanya, Shanghai, Shenyang
2024-02-29
Active, closed
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
NCT04556253MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University
Phase 2
47
Beijing
2024-02-28
Recruiting
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05935215Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals
Phase 3
50
Nanjing, Beijing, Shanghai
2024-02-28
Recruiting
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
NCT06252298Relapsed or Refractory Hematologic Malignancies
Sinocelltech Ltd.
Phase 1
74
Beijing
2024-02-28
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
Daiichi Sankyo
Phase 2/3
860
Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai
2024-02-27
Recruiting
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
NCT06292650Retinitis Pigmentosa
Zhongmou Therapeutics
Phase EARLY_PHASE1
12
Beijing
2024-02-25
Recruiting
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Hefei, Hangzhou, Wenzhou, Beijing
2024-02-23
Recruiting
Prognostic Prediction Model of Patients With AcUte Stroke undeRgoing EndOvascular TheRApy (AURORA)
NCT06009315Acute Ischemic Stroke
Beijing Tiantan Hospital
Observational
949
Beijing
2024-02-23
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06221748Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
NCT06271837Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
NCT06232096Relapsed or Refractory Multiple Myeloma
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
154
Beijing
2024-02-22
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Recruiting
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
NCT06210490Upper Urinary Tract Urothelial Carcinoma
Peking University First Hospital
Phase 2
60
Beijing
2024-02-20
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Recruiting
Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy
NCT06248333Epilepsy, Drug Resistant
Xuanwu Hospital, Beijing
Not applicable
33
Beijing
2024-02-14
Recruiting
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
NCT06211114Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2024-02-09
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Active, closed
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06238544Paroxysmal Nocturnal Hemoglobinuria
Chengdu Suncadia Medicine Co., Ltd.
Phase 2
132
Beijing, Tianjin
2024-02-06
Active, closed
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
NCT06169722GVHD, Chronic
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
60
Beijing
2024-02-06
Recruiting
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
NCT06122389Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
130
Beijing
2024-02-05
Recruiting
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
NCT06194734Esophageal Squamous Cell Carcinoma
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3
490
Beijing
2024-02-05
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
Recruiting
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
NCT06086457Esophageal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
436
Beijing
2024-02-04
Recruiting
Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer๏ผˆIDEAL Stage 2b๏ผ‰
NCT06788548Early Gastric Cancer
Beijing Friendship Hospital
Not applicable
312
Beijing
2024-02-03
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
NCT06253234WHO Grade III Gliomas, WHO Grade IV Gliomas
Beijing Tiantan Hospital
Phase 1
12
Beijing
2024-02-02
Recruiting
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
NCT06583070Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
Peking University First Hospital
Observational
300
Beijing
2024-02-02
Recruiting
A Comprehensive Registry Study of the Whole Life Cycle of Patients With CHD
NCT06611787Congenital Heart Disease
Beijing Anzhen Hospital
Observational
100,000
Beijing
2024-02-02
Recruiting
Peking University Birth Cohort in Weifang (PKUBC-WF)
NCT06234332Health Problems in Pregnancy, Pregnancy Outcomes, Gestational Diabetes, Gestational Hypertension
Peking University
Observational
2,800
Beijing
2024-02-01
Active, closed
Superior Vena Cava Isolation Plus Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
NCT06183619Atrial Fibrillation
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
400
Beijing
2024-02-01
Recruiting
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
NCT06251687Pulmonary Fibrosis, Transbronchial Cryobiopsy
China-Japan Friendship Hospital
Not applicable
100
Beijing
2024-02-01
Recruiting
A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma
NCT05962892Papillary Thyroid Carcinoma, Thermal Ablation
Beijing Friendship Hospital
Observational
600
Beijing
2024-02-01
Recruiting
Oxygen Concentration Target in Stroke Endovascular Treatment
NCT06224426Ischemic Stroke
Beijing Tiantan Hospital
Not applicable
200
Beijing
2024-02-01
By invitation
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
NCT06811025Tuberculosis, Meningitis
Beijing Chest Hospital
Phase 1/2
24
Beijing
2024-02-01
Not yet open
A Randomized Controlled Trial for Surgical Treatment of Recurrent Adult Tethered Cord Syndrome
NCT06197399Recurrent Adult Tethered Cord Syndrome
Xuanwu Hospital, Beijing
Not applicable
222
Beijing
2024-02-01
Recruiting
Non-Invasive Model for Fibrosis Regression in HBV Patients
NCT06874127Chronic Hepatitis B Virus (HBV) Infection, Liver Fibrosis
Beijing Friendship Hospital
Observational
1,100
Beijing
2024-02-01
Recruiting
Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
NCT06779864Chronic Hepatitis B
Beijing Friendship Hospital
Observational
2,000
Beijing
2024-02-01
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan
2024-02-01
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne
NCT06311890Acne, Photodynamic Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 2
46
Beijing
2024-02-01
Recruiting
Postoperative Anemia After Bariatric Surgery
NCT06198790Anemia, Bariatric Surgery Candidate
China-Japan Friendship Hospital
Observational
400
Beijing
2024-02-01
Recruiting
The Therapeutic Effect of Thalidomide in Syringomyelia
NCT06268093Syringomyelia, Thalidomide
Xuanwu Hospital, Beijing
Phase 2
30
Beijing
2024-02
By invitation
Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis
NCT06811012Tuberculosis, Bone, Joint
Beijing Chest Hospital
Phase 1/2
24
Beijing
2024-01-31
Recruiting
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
NCT06543069Malignant Peritoneal Mesothelioma, Advanced
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
28
Beijing
2024-01-31
Recruiting
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580Malignant Melanoma, Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1/2
96
Beijing
2024-01-31
Not yet open
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
NCT06132217Advanced Solid Tumor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2
168
Beijing
2024-01-30
Not yet open
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
NCT06245824Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4
51
Beijing
2024-01-30
Recruiting
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
NCT05947916Type2diabetes, Pregnancy Related, Continuous Glucose Monitoring, Time in Range
Peking University Third Hospital
Not applicable
240
Beijing
2024-01-30
Active, closed
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
NCT05894889Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Peking University
Phase 2
70
Beijing, Shanghai
2024-01-30
Active, closed
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
NCT06265428HER2-positive Breast Cancer
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease
NCT06742450Parkinson's Disease (PD)
Xuanwu Hospital, Beijing
Not applicable
180
Beijing
2024-01-27
Recruiting
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
NCT06733051Natural Killer T-cell Lymphoma
Sun Yat-sen University
Phase 2
47
Beijing, Guangzhou
2024-01-27
Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156Advanced Melanoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Recruiting
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06244992Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics, Inc.
Phase 1/2
68
Guangzhou, Beijing
2024-01-26
Recruiting
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
NCT06205472Hepatocellular Carcinoma, Narrow Margin, Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
100
Beijing
2024-01-26
Recruiting
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
NCT05634057Sepsis
Chen Ying
Not applicable
782
Beijing
2024-01-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Active, closed
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06206733Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
AskGene Pharma, Inc.
Phase 3
780
Beijing
2024-01-25
Active, closed
A RCT of Low MBO Drainage Strategies
NCT06196164Jaundice, Obstructive, Cholangiopancreatography, Endoscopic Retrograde, Endoscopic Ultrasound-Guided Drainage
Peking Union Medical College Hospital
Not applicable
40
Beijing
2024-01-25
Recruiting
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
NCT06164314Postoperative Delirium
Beijing Tiantan Hospital
Not applicable
366
Beijing
2024-01-25
Recruiting
Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes
NCT06087510Scoliosis Correction, Postoperative Analgesia, Esketamine, Dexmedetomidine
Peking University First Hospital
Phase 4
312
Beijing
2024-01-24
Active, closed
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
NCT06404905Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Recruiting
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069SCLC
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
152
Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao
2024-01-23
Recruiting
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06793813Stage IVB Lung Cancer, Non-Squamous
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
44
Beijing
2024-01-23
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
AstraZeneca
Phase 1/2
161
Beijing, Guangzhou, Shanghai
2024-01-23
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Recruiting
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B
NCT06525909Hepatitis B, Chronic
Tongji Hospital
Observational
250
Wuhan, Beijing, Changchun, Chongqing, Nanjing
2024-01-20
Recruiting
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
NCT06203249Microbiome, Immune Function, Anti-MDA5 Antibody Positive Dermatomyositis
Chinese PLA General Hospital
Observational
50
Beijing
2024-01-20
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
NCT06055452Pre-Heart Failure, Hypertension
China National Center for Cardiovascular Diseases
Phase 4
120
Beijing, Shenzhen
2024-01-19
Recruiting
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
NCT06031584Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
42
Beijing
2024-01-19
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DualityBio Inc.
Phase 3
541
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Huizhou
2024-01-18
Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca
Phase 1/2
334
Beijing, Chengdu, Shanghai, Wuhan
2024-01-18
Recruiting
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
NCT06342336Solid Tumor
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 1
44
Beijing
2024-01-18
Recruiting
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
NCT06167681Parkinson Disease
iRegene Therapeutics Co., Ltd.
Phase 1/2
40
Beijing, Wuhan
2024-01-17
Recruiting
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
NCT06209099Rectal Cancer
Peking University Cancer Hospital & Institute
Not applicable
96
Beijing
2024-01-17
Recruiting
Effectiveness of OLE Airway Clearance Therapy in ICU Patients With Pulmonary Infections
NCT07395297Pneumonia
Chinese PLA General Hospital
Not applicable
62
Beijing
2024-01-15
Recruiting
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT06671548Heavy Menstrual Bleeding, Uterine Fibroids
Qilu Pharmaceutical Co., Ltd.
Phase 3
120
Beijing
2024-01-15
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Active, closed
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
NCT06099236Atypical Hemolytic Uremic Syndrome(aHUS)
AstraZeneca
Observational
367
Beijing, Chongqing, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Hainan
2024-01-15
Recruiting
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NCT06197581Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
148
Beijing
2024-01-12
Rows per page Showing 3701–3800 of 5484
Previous 36 37 38 39 40 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=38

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.